Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alexander H. Pearlman"'
Autor:
Katharine M. Wright, Sarah R. DiNapoli, Michelle S. Miller, P. Aitana Azurmendi, Xiaowei Zhao, Zhiheng Yu, Mayukh Chakrabarti, WuXian Shi, Jacqueline Douglass, Michael S. Hwang, Emily Han-Chung Hsiue, Brian J. Mog, Alexander H. Pearlman, Suman Paul, Maximilian F. Konig, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Sandra B. Gabelli
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific therapeutic targets. MANAs are HLA-presented (pHLA)
Externí odkaz:
https://doaj.org/article/5c61b5ab3e274b5e8cb75d96c8090383
Autor:
Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi, Andrew D. Skora, Alexander H. Pearlman, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Chetan Bettegowda, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Sandra B. Gabelli
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented neoan
Externí odkaz:
https://doaj.org/article/fff72ea490f640af8b0aeee032442ea5
Autor:
Brian J. Mog, Sarah R. DiNapoli, Michael S. Hwang, Tushar D. Nichakawade, Jacqueline Douglass, Emily Han-Chung Hsiue, Katharine M. Wright, Alexander H. Pearlman, Maximilian F. Konig, Suman Paul, Nicolas Wyhs, Nikita Marcou, Stephanie Glavaris, Jiaxin Ge, Michelle S. Miller, P. Aitana Azurmendi, Evangeline Watson, Drew M. Pardoll, Sandra B. Gabelli, Chetan Bettegowda, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou
Publikováno v:
Cancer Research. 83:LB095-LB095
Mutation-associated neoantigens (MANAs) are exquisitely cancer-specific therapeutic targets. However, MANAs are present at ultra-low densities on the cancer cell surface (as few as 1-2 copies per cell), leading to the challenge of eliciting a suffici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::852b8472e018ff12cccefdaccb7f0beb
https://doi.org/10.1158/1538-7445.am2023-lb095
https://doi.org/10.1158/1538-7445.am2023-lb095
Autor:
Maximilian F. Konig, Alexander H. Pearlman, Michael S. Hwang, Chetan Bettegowda, Nicholas Papadopoulos, Jacqueline Douglass, Sandra B. Gabelli, Sarah R. DiNapoli, Kenneth W. Kinzler, Shibin Zhou, Drew M. Pardoll, Bert Vogelstein, Brian J. Mog, Emily Han-Chung Hsiue
Publikováno v:
Nat Cancer
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f030532034a82edfbe35029209daf7
https://pubmed.ncbi.nlm.nih.gov/34676374
https://pubmed.ncbi.nlm.nih.gov/34676374
Autor:
Chetan Bettegowda, Alexander H. Pearlman, Bert Vogelstein, Nicholas Papadopoulos, Brian J. Mog, Sandra B. Gabelli, Kenneth W. Kinzler, Shibin Zhou, Maximilian F. Konig, Jacqueline Douglass, Drew M. Pardoll, Sarah R. DiNapoli, Michael S. Hwang, Emily Han-Chung Hsiue
Publikováno v:
Nature cancer. 2(5)
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29aa31e6417bdc746f71a76c49b8f9b8
https://pubmed.ncbi.nlm.nih.gov/35122030
https://pubmed.ncbi.nlm.nih.gov/35122030
Autor:
Nickolas Papadopoulos, Jacqueline Douglass, Brian J. Mog, Suman Paul, Michael S. Hwang, Bert Vogelstein, Emily Han-Chung Hsiue, Drew M. Pardoll, Maximilian F. Konig, Sandra B. Gabelli, Kenneth W. Kinzler, Shibin Zhou, Sarah R. DiNapoli, Alexander H. Pearlman, Chetan Bettegowda
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance The lack of viable tumor-specific targets continues to thwart efforts to implement selective anticancer drugs in the clinic. Clonal loss of heterozygosity (LOH) occurs in the great majority of human tumors and represents an irreversible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02c75a00300f9991e716d0bc1db11eb
https://doi.org/10.1073/pnas.2022410118
https://doi.org/10.1073/pnas.2022410118
Autor:
Qing Wang, Michael B. Murphy, Chetan Bettegowda, Annika Schaefer, Emily Han-Chung Hsiue, Alexander H. Pearlman, Liu Qiang, Drew M. Pardoll, Andrew D. Skora, Bert Vogelstein, Sarah R. DiNapoli, Katharine M. Wright, Evangeline Watson, Nickolas Papadopoulos, Brian J. Mog, Michelle S. Miller, Suman Paul, Michael S. Hwang, Jacqueline Douglass, P. Aitana Azurmendi, Maximilian F. Konig, Yana Li, Sandra B. Gabelli, Kenneth W. Kinzler, Shibin Zhou
Publikováno v:
Science
Turning a tumor suppressor into a target Tumor-suppressor genes such as TP53 (tumor protein P53) play key roles in the pathogenesis of cancer but, unfortunately, they are difficult to target because they do not create an overactive protein that can b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed2d9d305574efc36b10dfe4b16e8b8
https://doi.org/10.1126/science.abc8697
https://doi.org/10.1126/science.abc8697
Autor:
Qing Wang, Suman Paul, Sandra B. Gabelli, Liu Qiang, Emily Han-Chung Hsiue, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Yana Li, Jacqueline Douglass, Annika Schaefer, Alexander H. Pearlman, Evangeline Watson, Brian J. Mog, Andrew D. Skora, Sarah R. DiNapoli, Katharine M. Wright, Michael S. Hwang, Maximilian F. Konig, Michael B. Murphy, Marco Dal Molin, Chetan Bettegowda, Drew M. Pardoll, Bert Vogelstein, Michelle S. Miller, P. Aitana Azurmendi
Publikováno v:
Sci Immunol
Mutations in the RAS oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these efforts are focused on conventional small-molecule drugs rather than antibody-based thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a940be3f47c9ded29508c29af1e06b
https://doi.org/10.1126/sciimmunol.abd5515
https://doi.org/10.1126/sciimmunol.abd5515
Autor:
Jacqueline Douglass, Puchong Thirawatananond, Katharine M. Wright, Andrew D. Skora, Emily Han-Chung Hsiue, Tihitina Aytenfisu, Sandra B. Gabelli, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Michael B. Murphy, Bert Vogelstein, Brian J. Mog, Sarah R. DiNapoli, Michael S. Hwang, Drew M. Pardoll, P. Aitana Azurmendi, Alexander H. Pearlman, Michelle S. Miller, Suman Paul, Maximilian F. Konig, Chetan Bettegowda
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of human cancers. One major challenge precluding the wider implementation of CAR therapy is th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3280c4700375b6ff6bc95473802942b
https://pubmed.ncbi.nlm.nih.gov/34489470
https://pubmed.ncbi.nlm.nih.gov/34489470
Autor:
Aarat Patel, Rashmi Sinha, Pankti Reid, Alexander H. Pearlman, Isabelle Amigues, Philip Robinson, Taryn Youngstein, Alfred Hj Kim, Arundathi Jayatilleke, Maximilian F. Konig
Publikováno v:
Expert Rev Clin Immunol
Expert Review of Clinical Immunology
Expert Review of Clinical Immunology
Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by an injurious immune response characterized by the development of acute respiratory distress syndrome (ARDS), endotheliitis, coagulopathy, and multi-organ failu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55dc4726f5a8b1dff6c582d90e1f4b26
https://pubmed.ncbi.nlm.nih.gov/33146561
https://pubmed.ncbi.nlm.nih.gov/33146561